2025–2029 Anti-Asthmatics And COPD Drugs Market Outlook: Regional Trends and Growth Forecast
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Does the Forecast Indicate for the Anti-Asthmatics And COPD Drugs Market From 2025 to 2029?
In recent years, there has been a robust growth in the market size of anti-asthmatics and COPD drugs. Projected to rise from $80.85 billion in 2024 to $85.08 billion in 2025, the market is anticipated to expand at a compound annual growth rate (CAGR) of 5.2%. Factors contributing to this historical growth include a higher prevalence of respiratory illnesses, a rise in tobacco smoking incidents, the effect of global warming, an aging population, the emergence of new markets, innovative drug discovery methods, and an increase in healthcare spending.
The market for anti-asthmatics and COPD drugs is poised for robust growth in the upcoming years, predicted to expand to a worth of $105.07 billion by 2029, boasting a compound annual growth rate (CAGR) of 5.4%. The growth in the projected period is owing to factors like burgeoning popularity of e-cigarettes/vaping, increasing obesity levels, technological advancements, a significant undiagnosed population base, the usage of anti-asthmatics and COPD drugs for treating COVID-19 patients, and growing fat consumption. The market’s future trends encompass the development of probiotic drugs for asthma, creation of anti-il-5 medications to diversify business portfolios, the launch of innovative new products to solidify market standing and maintain competitiveness, more investment in bioelectric medicine research, focus on boosting collaboration numbers, the provision of personalized treatment options, and creation of combination drugs for enhanced outcomes, and developing biologics in response to the escalating demand.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3802&type=smp
What Elements Are Contributing To Growth In The Anti-Asthmatics And COPD Drugs Market?
The anti-asthmatics and COPD drugs market is significantly influenced by alterable risk factors such as unhealthy eating, smoking, and insufficient physical activity. Despite the overall global decrease in smoking rates, developing nations such as China, India, Indonesia, and Nigeria are experiencing a rise in smoking prevalence. For example, by 2025, the number of tobacco users in Indonesia is predicted to rise by 24 million and 7 million in Nigeria, with more than 40% of total worldwide cigarette consumption occurring in China. In wealthy countries like the USA and Europe, the consumption of fats, including saturated fatty acids, known risk factors for Asthma and COPD, is higher. As per the World Health Organization, fat contributes over 35% of the total energy requirement in developed countries, which is much higher than in low income (<20%) or lower-middle income countries (<25%).
Which Segments Are Detailed In The Global Anti-Asthmatics And COPD Drugs Market Report?
The anti-asthmatics and copd drugs market covered in this report is segmented –
1) By Drug Class: Bronchodilators, Anti-Inflammatory Drugs, Monoclonal Antibodies, Combination Drugs
2) By Distribution Channel: Hospital Pharmacies, General Pharmacies, Online Retailers
3) By End User: Asthma Patients, COPD Patients
4) By Therapy: Preventive, Curative
5) By Route Of Administration: Oral, Inhaled, Intravenous, Subcutaneous
6) By Age Group: Below 5, 5-14, 15-60, Above 60
Subsegments:
1) By Bronchodilators: Short-Acting Beta-Agonists (SABAs), Long-Acting Beta-Agonists (LABAs), Anticholinergics (Short-Acting And Long-Acting), Methylxanthines
2) By Anti-Inflammatory Drugs: Corticosteroids (Inhaled And Systemic), Leukotriene Modifiers, Phosphodiesterase-4 Inhibitors
3) By Monoclonal Antibodies: Anti-IgE Antibodies, Anti-IL-5 Antibodies, Anti-IL-4 Or IL-13 Antibodies
4) By Combination Drugs: Combination Bronchodilator Inhalers (LABA + LAMA), Inhaled Corticosteroid + Long-Acting Beta-Agonist (ICS + LABA)
Which Emerging Trends And Strategic Shifts Are Shaping The Anti-Asthmatics And COPD Drugs Market?
Prominent businesses in the alpha mannosidosis market are concentrating on the innovation of enzyme replacement therapy for the rare disease alpha-mannosidosis. This therapy involves the provision of exogenous alpha-mannnosidase to decrease the build-up of mannose-rich oligosaccharides in various body tissues and organs. Such accumulation is a defining aspect of alpha-mannosidosis and contributes to its pathological effects. Take for instance, Chiesi Global Rare Diseases, a US-based pharmaceutical firm, which introduced Lamzede (velmanase alfa) in February 2023. It’s the first authorized enzyme replacement treatment available in the United States for treating alpha-mannosidosis. This rare genetic disorder is characterized by the absent alpha-mannosidase enzyme in the body and the symptoms it presents beyond the central nervous system. Lamzede acts similarly to the human body’s alpha-mannosidase enzyme, restoring normal cell activity in patients. Patients are given a 10 mg injection of Lamzede weekly.
Who Are The Key Contributors To Growth In The Anti-Asthmatics And COPD Drugs Market?
Major companies operating in the anti-asthmatics and COPD drugs market include GlaxoSmithKline plc, AstraZeneca plc, Boehringer Ingelheim GmbH, F. Hoffmann-La Roche Ltd., Novartis AG, Sanofi S.A., Chiesi Farmaceutici S.p.A., Teva Pharmaceutical Industries Limited, Merck & Co. Inc., Sumitomo Dainippon Pharma Co. Ltd., China National Pharmaceutical Group Co. Ltd. (Sinopharm), Shanghai Acebright Pharmaceuticals Group Co. Ltd., Jiangsu Hengrui Medicine Co. Ltd, Hanmi Pharmaceutical, Cipla Limited, Aurobindo Pharma Limited, KYORIN Holdings Inc., Nichi-Iko Pharmaceutical Co. Ltd., Otsuka Pharmaceutical Co. Ltd., Daewoong Pharmaceutical Co. Ltd, Shanghai Anovent Pharma, China Meheco Group Co. Ltd., Lupin Limited, ASGEN Pharmaceutical Co. Ltd, Abbott Laboratories, Pfizer, Vectura Group, Bristol Myers Squibb, Apotex Inc., EMS Pharma, Hypermarcas, Ache, Eurofarma, Bayer, Biolab Farmaceuticad, Cristalia, Libbs, Julphar, Neopharma, Adcock Ingram, Aspen Nigeria
Get The Full Report Here:
Which Region Is Projected To Lead The Anti-Asthmatics And COPD Drugs Market By 2025?
North America was the largest region in the anti-asthmatics and COPD drugs market in 2024. Middle East is expected to be the fastest-growing region in the global anti-asthmatics and COPD drugs market during the forecast period. The regions covered in the anti-asthmatics and COPD drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=3802&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
